Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
clinical trials
life sciences
national blog main
national top stories
new york blog main
san diego blog main
akcea therapeutics
anylam pharmaceuticals
astellas pharma
atlas venture
audentes therapeutics
avidity biosciences
biotech
bluebird bio
boston
cardiomyopathy
drugs
duchenne muscular dystrophy
dyne therapeutics
facioscapulohumeral muscular dystrophy
gene therapy
inotersen
joshua brumm
kaleido biosciences
muscular dystrophy
myotonic dystrophy type 1
neuropathy
new york
new york top stories
onpattro
patisiran
pfizer
rare disease drugs
romesh subramanian
san diego top stories
san francisco blog main
susanna high
tafamidis
What
ago
2
×
drug
genetic
medicines
2
×
rare
2
×
akcea
alnylam
amyloidosis
approved
attr
available
battle
biotechs
considering
data
debilitating
disease
diseases
dyne
early
expected
experimental
eyes
fda
having
humans
ipo
ipos
long
muscle
oks
patients
pfizer
reach
sets
therapeutics
transthyretin
worked
year
Language
unset
Current search:
ago
×
medicines
×
rare
×
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
4 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
